AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Amarin Responds to Inaccurate and Misleading Statement by Sarissa

19 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders

11 Jan 2023 15:33:31 By Nasdaq GlobeNewswire

Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023

10 Jan 2023 06:15:00 By Nasdaq GlobeNewswire

Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP

10 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference

14 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland

07 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia

15 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Amarin to Present at Jefferies London Healthcare Conference

09 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care

07 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update

27 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors

20 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022

20 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Amarin Board of Directors Issues Statement in Response to Sarissa

11 Oct 2022 15:15:00 By Nasdaq GlobeNewswire

Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference

30 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

28 Aug 2022 04:51:07 By Nasdaq GlobeNewswire

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

26 Aug 2022 07:19:00 By Nasdaq GlobeNewswire

Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress

15 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update

03 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022

20 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales

13 Jul 2022 07:00:01 By Nasdaq GlobeNewswire